Biostage Inc (BSTG) Given a $3.00 Price Target at Maxim Group

Maxim Group set a $3.00 price target on Biostage Inc (NASDAQ:BSTG) in a research report report published on Friday. The firm currently has a a buy rating on the stock.

Shares of Biostage (NASDAQ:BSTG) traded down 1.0532% during trading on Friday, hitting $0.9301. 35,607 shares of the stock were exchanged. The firm has a 50 day moving average price of $1.04 and a 200 day moving average price of $1.35. Biostage has a 52 week low of $0.53 and a 52 week high of $3.47. The firm’s market capitalization is $15.91 million.

Biostage (NASDAQ:BSTG) last posted its earnings results on Thursday, August 11th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.04. Analysts forecast that Biostage will post ($0.86) EPS for the current fiscal year.

About Biostage

Biostage, Inc, formerly Harvard Apparatus Regenerative Technology, Inc, is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient’s own cells.

5 Day Chart for NASDAQ:BSTG

Receive News & Ratings for Biostage Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostage Inc and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.